Definium Therapeutics, Inc. (DFTX)
Healthcare
Biotechnology
—
43.50 $
-2.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Definium Therapeutics, Inc. (DFTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -43 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14 | -17 | -21 | -17 | -20 | -17 | -25 | -29 | -30 | -30 | -42 | -43 | -144 | |
| 0.8 | 0.8 | 0.8 | 0.5 | – | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 0.6 | |
| 3.8 | 4.2 | 3.7 | 3.7 | 5.4 | 3.8 | 3.4 | 3.4 | 5.3 | 5.8 | 11 | 7.1 | 30 | |
| 9.5 | -1.1 | -3.8 | -0.7 | -3.5 | 4.1 | -0.2 | -2.5 | 8.1 | 8.1 | -4.5 | 5.4 | 17 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| – | – | – | – | – | – | – | -162 | -40 | 15 | 38 | 42 | 55 | |
| – | – | – | – | – | 0.1 | 1.0 | 0.0 | 20 | 0.4 | 0.0 | – | – | |
| 1.3 | 17 | 2.6 | 169 | 11 | 69 | 3.8 | 1.0 | 20 | 0.7 | 247 | 5.3 | 272 | |
| -13 | 0.8 | -18 | 153 | -9.2 | 52 | -22 | -191 | -49 | -13 | 238 | 4.7 | 180 | |
| -14 | -17 | -21 | -17 | -20 | -17 | -25 | -29 | -30 | -30 | -42 | -43 | -144 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.